glp-1 and alzheimer's disease 🧐Will GLP-1RA drugs be the future of altzeimers treatement? 🧠There are multiple studies underway assessing the effectiveness of class of medications in prevention and/or delay of dementia 🧠Alzheimer's makes up 60%-80% Glucagon-like peptide-1 medicines in neurological
Description
PERK, PKR-like ER kinase
Mazdutide, a dual glucagon and GLP-1 agonist, is approved
GLP-1 RA-exposed pregnancies compared to matched control groups When estimating the Average Treatment Effect on the Treated (ATT), we did not observe any differences in birth weight, placental weight or the frequency of SGA or LGA, GDM or pre-eclampsia between GLP-1 RA exposure and any of the six control groups (Fig
3 FDA Drug Safety Communication: NSAIDs and increased risk of heart attack or stroke
Diabetes 61, 27532762
